Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-arm, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effectiveness of TRS005 in Patients With Relapsed or Refractory CD20-positive B-NHL

NCT05395533 is registered in ClinicalTrials.gov with Zhejiang Teruisi Pharmaceutical Inc. as lead sponsor.

NCT NCT05395533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05395533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-arm, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effectiveness of TRS005 in Patients With Relapsed or Refractory CD20-positive B-NHL
Lead sponsor
Zhejiang Teruisi Pharmaceutical Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 8, 2020
Completion date
December 31, 2025
Enrollment
147 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cd20-positive b-cell non-hodgkin lymphoma